Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 3/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13254092 | 1.00 | CHRM3 (0.39) | CHRM3L3MBTL1POLBHTTGLP1R | |
| SCHEMBL13337024 | 1.00 | CHRM3 (0.39) | CHRM3L3MBTL1POLBHTTGLP1R | |
| SCHEMBL26724143 | 0.84 | CHRM3 (0.40) | CHRM3L3MBTL1POLBHTTGLP1R | |
| SCHEMBL26728235 | 0.84 | CHRM3 (0.42) | CHRM3L3MBTL1POLBACEREN | |
| SCHEMBL24579154 | 0.84 | CHRM3 (0.42) | CHRM3L3MBTL1POLBACEREN | |
| SCHEMBL24577997 | 0.84 | CHRM3 (0.40) | CHRM3L3MBTL1POLBHTTGLP1R | |
| SCHEMBL10021553 | 0.84 | CHRM3 (0.42) | CHRM3L3MBTL1POLBACEREN | |
| SCHEMBL22606372 | 0.83 | CHRM3 (0.38) | CHRM3L3MBTL1POLBHTTGLP1R | |
| SCHEMBL14375479 | 0.82 | CHRM3 (0.39) | CHRM3L3MBTL1POLBHTTGLP1R | |
| Lithium Ion SCHEMBL29760022 | 0.81 | CHRM3 (0.38) | CHRM3L3MBTL1POLBHTTGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357654-B2 | Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-01-22 | — | — | US | disclosed |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | disclosed |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CD40, CD40LG, TNFSF10 | CHRM3 159/4885L3MBTL1 2531/4885POLB 3609/4885 |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | TNFRSF1A, TNFRSF9, CD40 | CHRM3 1499/4885L3MBTL1 4575/4885POLB 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.